facebooktwitterlinkedin
Health Resources Hub / Men's Health / Benign Prostatic Hyperplasia

Newly Identified Prostate Cells May Explain Where Enlarged Prostate Takes Hold

Johns Hopkins researchers found a distinct type of prostate cell concentrated in the area where BPH develops, offering a possible clue to why the gland enlarges with age.

By

Lana Pine

Published on November 17, 2026

Fact checked by:

Afton Woodward

4 min read

Researchers at Johns Hopkins have identified a distinct type of prostate cell that may help explain one of the long-standing puzzles of benign prostatic hyperplasia (BPH): why the noncancerous enlargement almost always develops in the same part of the gland.

The study, published in The Journal of Pathology, found that these cells were highly concentrated in the region surrounding the urethra where BPH typically develops, and that they were significantly more abundant in prostate tissue from men with BPH. The team included Vasan Yegnasubramanian, M.D., Ph.D., Rulin Wang, M.D., and Angelo De Marzo, M.D., Ph.D., professor of pathology at the Johns Hopkins University School of Medicine.

An Enlarged Prostate and Its Effect on Urination

BPH is an overgrowth of prostate cells that becomes increasingly common with age. As the prostate enlarges, it can squeeze the urethra and interfere with the flow of urine, causing frequent or nighttime urination, a weak urine stream and difficulty completely emptying the bladder.

The prostate is divided into several zones, and they behave differently. BPH arises almost exclusively in the transition zone, while most prostate cancers develop in the peripheral zone.

Hormone changes, inflammation and cell growth are thought to play a role in BPH. But scientists still do not fully understand why the condition targets just one area, said senior author Yegnasubramanian, professor of oncology, pathology, and radiation oncology and molecular radiation sciences at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Mapping Nearly 130,000 Prostate Cells

To look for answers, the team analyzed noncancerous prostate tissue from 10 men who had prostate cancer, taken from the gland’s three main zones. Using single-cell RNA sequencing, a technology that shows which genes are active in individual cells, they examined nearly 130,000 individual cells.

They found four types of basal cells, which line the prostate’s glands. One subtype, marked by high activity of a gene called WIF1, was concentrated in the transition zone. Additional lab tests confirmed that these WIF1-positive basal cells were abundant in the transition zone but nearly absent from the peripheral and central zones.

When the researchers checked previously published data, they found that WIF1-positive basal cells were significantly more common in BPH than in normal prostate tissue.

Clues to How the Gland Grows

The cells showed activity in biological programs related to cell proliferation, immune regulation, blood vessel formation and hormone signaling. Some of the related genes respond to androgens such as testosterone and are involved in signaling pathways that influence prostate growth.

According to first author Wang, a research associate at Johns Hopkins, the cells may help establish the unique biological environment of the transition zone. The researchers also suggested the cells could help explain why prostate cancer begins less often in the transition zone.

Early Science, Not a New Treatment

The findings are preliminary. The tissue came from only 10 men, all with prostate cancer, so the findings may not apply to men without cancer. The study shows an association, not proof that these cells cause enlargement.

If these cells really do play a direct role in BPH, they could become future drug targets for preventing or treating the condition.

For now, the study doesn’t change how BPH is diagnosed or treated. Men with urinary symptoms have a range of options, from lifestyle changes and medications to minimally invasive procedures and surgery. They can talk with a primary care physician or urologist about which approach fits their symptoms and goals.

© 2026 MJH Life Sciences®

All rights reserved.